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Introduction {#sec1}
============

Hematopoietic stem cells (HSCs) differentiate via multiple progressively committed progenitor cell populations to maintain a balanced number of mature blood cells. Despite extensive investigation, the lineage potential, heterogeneity, and relationships of hematopoietic stem and progenitor cells (HSPCs) are under intense debate. Data from both single-cell transplantation and barcoding analyses support the existence of long-term, multilineage reconstituting clonal HSCs ([@bib13], [@bib16], [@bib22], [@bib30], [@bib44], [@bib45]). However, differential lineage contribution from single cells suggests heterogeneity even within strictly defined HSC compartments ([@bib6], [@bib44]). Similarly, the heterogeneity and physiological roles of hematopoietic progenitor cells are hotly debated. Evidence from multiple studies indicates that FLK2-positive multipotent progenitors (MPP^F^) serve as a developmental intermediate for all hematopoietic lineages, prior to the generation of progenitors restricted to either myeloid (common myeloid progenitors, CMPs) or lymphoid (common lymphoid progenitors, CLPs) fates ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib2], [@bib3], [@bib8], [@bib7], [@bib15], [@bib20], [@bib37]). While the existence of multipotent HSCs is widely accepted and recent *in situ* evidence supports the existence of multilineage progenitor cells ([@bib7], [@bib9], [@bib41]), the degree of lineage commitment of hematopoietic populations remains controversial.

Several factors have made it difficult to assess the level of lineage commitment and lineage bias within hematopoietic subtypes. Tracking of mature red blood cell (RBC) and platelet (Plt) production from hematopoietic progenitor subsets *in vivo* was developed relatively recently; therefore, the full spectrum of mature cell types is rarely simultaneously assessed. Substitute assays, such as hematopoietic differentiation *in vitro*, do not always accurately reflect differentiation *in situ* or upon transplantation *in vivo* ([@bib8], [@bib34], [@bib37]). In addition, mature cell output from transplanted hematopoietic subtypes is seldom measured quantitatively, precluding accurate comparison of lineage output from specific hematopoietic subsets. Here, we use side-by-side absolute quantification of mature cell production and single-cell *in vivo* assays to address the lineage contribution and functional heterogeneity of HSPCs. Our new insights were combined with previous data into a model of hematopoietic differentiation that reconciles multiple longstanding controversies in HSC biology.

Results {#sec2}
=======

Lineage Potential of Hematopoietic Cell Populations by Traditional Donor Chimerism {#sec2.1}
----------------------------------------------------------------------------------

To qualitatively and quantitatively assess the differentiation potential of distinct HSPC populations ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), we performed comprehensive analyses of mature cell production upon transplantation into sublethally irradiated mice. UBC-GFP mice allowed for the simultaneous detection of donor-derived RBCs, platelets, granulocytes/myelomonocytes (GMs), and B and T cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C). To enable detection of rare and transiently generated cell types, the peripheral blood (PB) of recipient mice was monitored at frequent and early time points post-transplantation.

We first displayed reconstitution as donor chimerism (donor-derived cells relative to host cells), as is commonly done ([Figures 1](#fig1){ref-type="fig"}A--1G and [S1](#mmc1){ref-type="supplementary-material"}D). Aside from a few notable exceptions and the addition of RBC analysis, our results largely agreed with previous reports ([@bib2], [@bib12], [@bib15], [@bib29], [@bib44]). Thus, HSCs gave rise to all five lineages analyzed, without evidence of decline for the duration of the experiments (16 weeks) ([Figure 1](#fig1){ref-type="fig"}A). MPP^F^ also gave rise to all five lineages analyzed, with clear declines in chimerism 21--51 days post-transplantation ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}D). Interestingly, although the Plt contribution from MPP^F^ was lower than GM, B cell, or T cell chimerism, as reported previously ([@bib15], [@bib21]), the RBC chimerism was similar to that of nucleated white blood cells. Both FLK2^−^ and FLK2^+^ CMPs produced detectable levels of RBCs, platelets, and GMs, but not B and T cells, in the PB ([Figures 1](#fig1){ref-type="fig"}C, 1D, and [S1](#mmc1){ref-type="supplementary-material"}D). GM progenitors (GMPs), myeloerythroid progenitors (MEPs), and CLP^F^ contributed primarily to GMs, RBCs, and B cells, respectively ([Figures 1](#fig1){ref-type="fig"}E--1G and [S1](#mmc1){ref-type="supplementary-material"}D). Overall, these results agree with the lineage potential previously attributed to each of the HSPC populations.Figure 1Reconstitution Potential of Transplanted Hematopoietic Stem and Progenitor Cell Populations(A--G) Percentage donor chimerism over 110 days from HSCs (A), MPP^F^ (B), CMPs (C), CMP^F^ (D), GMPs (E), MEPs (F), or CLP^F^ (G) upon transplantation into sublethally irradiated (500 rad) mice.(H) B cell numbers display a rapid and more drastic decline (1,000-fold) after sublethal irradiation than other mature cell types (1.4-, 6-, 6-, and 23-fold for RBCs, platelets, GMs, and T cells, respectively). Data displayed are fold changes in mature cell numbers in the peripheral blood (PB) of sublethally irradiated (500 rad) mice over time. n ≥ 7.(I) The number of mature hematopoietic cells in a microliter of PB at steady state. n = 10.(J) The distribution of mature hematopoietic cells between blood, bone marrow, spleen, thymus, and lymph nodes of a mouse. n = 10.(K) The composition of mouse blood, bone marrow, spleen, thymus, and lymph nodes displayed as a percentage of total mature hematopoietic cells. n = 10.(L) The number of mature hematopoietic cells in a 25 g mouse at steady state. n = 10.(M--S) Reconstitution data from (A--G) replotted as the absolute number of donor-derived cells per microliter PB. HSCs (M), MPP^F^ (N), CMPs (O), CMP^F^ (P), GMPs (Q), MEPs (R), and CLP^F^ (S). Transplantation data in (A--G) and (M--S) are representative means ± SEM from at least seven recipient mice per cell type from at least two independent experiments.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Quantifying Absolute Numbers of Mature Cells Produced by Distinct Progenitor Populations {#sec2.2}
----------------------------------------------------------------------------------------

Reconstitution displayed as chimerism depends on both donor cell production and the number of mature host cells present. To compare the effects of radiation conditioning on different types of host cells, we measured mature cell numbers at several time points post-sublethal irradiation. This analysis uncovered a dramatically cell-type-specific variation in both the magnitude and the kinetics of host cell decrease and recovery, with a rapid, greater than 1,000-fold decrease in B cell numbers and only an ∼1.4-fold, slower, decrease in RBC numbers ([Figure 1](#fig1){ref-type="fig"}H). These host cell variations affect the perceived cell generation from transplanted cells when reconstitution is displayed as donor-to-host chimerism. To remove the host variable, we determined the absolute number of each donor-derived mature cell type in the PB after transplantation of different progenitor populations, displayed as the number of donor-derived cells per microliter of PB ([Figures 1](#fig1){ref-type="fig"}M--1S). Even though these data were derived from the same transplantation experiments as for [Figures 1](#fig1){ref-type="fig"}A--1G, the absolute quantification conveyed a remarkably different perspective on the ability of different progenitors to reconstitute hematopoiesis (compare [Figures 1](#fig1){ref-type="fig"}A--1G with 1M--1S): with the exception of CLPs, RBC production exceeded all other cell types by orders of magnitude from all transplanted progenitor populations.

To determine whether this RBC dominance was apparent only in the blood, we accounted for differential tissue distribution of each cell type to convey the total number of cells produced per transplanted HSPC in the entire body of the recipient. Assessments of mature cell numbers and tissue distribution between major hematopoietic organs revealed that, as expected, RBCs far outnumbered the other cell types in PB ([Figure 1](#fig1){ref-type="fig"}I) and that the vast majority of the total RBCs present in a mouse were located in the PB ([Figure 1](#fig1){ref-type="fig"}J). Platelets had a similar distribution pattern, whereas most GMs were found in the bone marrow (BM). B cells were distributed (in order of abundance) among BM, spleen, lymph nodes, and PB, and T cells among lymph nodes, spleen, thymus, BM, and PB. Conversely, displaying each tissue based on the abundance of cell types revealed that blood is composed almost entirely of RBCs (87%) and platelets (12%) and that CD3^+^ T cells make up 78% of the hematopoietic cells in the thymus, whereas other tissues were less dominated by one cell type ([Figure 1](#fig1){ref-type="fig"}K). Combining the tissue distribution with PB cell counts provided an estimate of the total numbers of each cell type in a mouse ([Figure 1](#fig1){ref-type="fig"}L) that are consistent with previous reports ([@bib18], [@bib26]).

These data enabled us to use the PB data ([Figures 1](#fig1){ref-type="fig"}M--1S) to assess the absolute number of each mature cell type generated by each transplanted cell population in each recipient mouse ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2G). While the magnitude of the difference between cells that mainly distribute to the blood (RBCs and platelets) and cell types that are dispersed among other tissues (GMs, B and T cells) decreased when whole-body distribution was taken into account, the relative order of cell types produced was not altered (compare [Figures 1](#fig1){ref-type="fig"}M--1S with [S2](#mmc1){ref-type="supplementary-material"}A--S2G; except for GMPs, see below). Using modified Markov birth-death modeling and published mature cell half-lives, we tested the impact of cell half-life (ranging from ∼1 day for GMs to ∼150 days for T cells) on population size. Because the identity and half-life of each intermediate population is not known, we modeled an "extreme half-life scenario" where the published half-life for each mature population was used for all progenitor intermediates giving rise to that cell type to estimate the largest possible impact of the differential half-lives ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). We then calculated a "birth rate" to distinguish *cell generation* (new cells produced; [Table S1](#mmc1){ref-type="supplementary-material"} and [Figure S2](#mmc1){ref-type="supplementary-material"}A′--S2G′) from *cell accumulation* (number of cells present; [Table 1](#tbl1){ref-type="table"}). Over time, the differential half-lives have a significant impact; thus, our estimations of cell production by HSCs are different in the short term ([Tables 1](#fig1){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}) and long term ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}). Importantly, because repopulation from progenitor cells is transient, half-lives have less impact on estimation of mature cell production by progenitor cells, especially during the early time points after transplantation that we used for cell quantification (compare [Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"} and solid and dashed lines in [Figures S2](#mmc1){ref-type="supplementary-material"}A′--S2G′; see [Figures 2](#fig2){ref-type="fig"}A′--2G′ for cell numbers and post-transplantation time points).Table 1Approximate Proportion of the Absolute Number of Mature Cells Generated by Each Transplanted Progenitor Cell TypeRBCPltGMBTHSC86.27.222.872.481.25MPP^F^98.30.560.470.310.33CMP99.70.260.01ndndCMP^F^99.40.290.31ndndGMP90.80.798.37ndndMEP99.90.12ndndndCLPndndnd919[^2]Figure 2Comparative Mature Cell Accumulation and Kinetics by Transplanted Hematopoietic Stem and Progenitor Cell PopulationsThe total numbers of RBCs (A), platelets (B), GMs (C), B cells (D), and T cells (E) present per mouse per transplanted HSPC. (A′--E′) The approximate time points and cell numbers for peak donor-derived mature cells from (A--E), respectively.Data were generated from the transplantation and cell distribution experiments of [Figure 1](#fig1){ref-type="fig"}. The mature cell production capacity was always in the same order: HSCs \> MPP^F^ \> CLP^F^ (for B and T cells) and HSCs \> MPP^F^ \> CMP \> CMP^F^ \> MEP \> GMP (for RBCs, platelets, and GMs). The only exception was that significantly more GMs accumulated after CMP^F^ than after CMP transplantation (C and C′; p \< 0.0009 by Student\'s two-tailed t test). All other comparisons were also significant. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

The absolute quantification revealed that RBCs were by far the most abundant cell type produced by each progenitor ([Figures 1](#fig1){ref-type="fig"}M--1S and [S2](#mmc1){ref-type="supplementary-material"}A--S2G and [Table 1](#tbl1){ref-type="table"}). The only exception was CLP^F^, which stayed true to their reported lymphoid commitment by producing only B and T cells ([Figure 1](#fig1){ref-type="fig"}S) ([@bib15], [@bib20], [@bib37]). Of note, T cell production by CLP^F^ was more readily detectable when displayed as absolute numbers ([Figures 1](#fig1){ref-type="fig"}S and [S2](#mmc1){ref-type="supplementary-material"}G) than as chimerism ([Figure 1](#fig1){ref-type="fig"}G). After RBCs, platelets were the next most abundant mature cell type produced. Despite the low Plt chimerism after transplantation of MPP^F^, CMPs, CMP^F^, MEPs, and GMPs ([Figures 1](#fig1){ref-type="fig"}B--1F), donor-derived platelets outnumbered or equaled the GMs, B cells, and T cells produced from each population ([Figures 1](#fig1){ref-type="fig"}N--1R and [S2](#mmc1){ref-type="supplementary-material"}B--S2F, [Table 1](#tbl1){ref-type="table"}). Surprisingly, GMPs, previously considered committed to myelomonocytic cell production ([@bib2], [@bib15], [@bib25]), produced more RBCs than GMs and also contributed to platelets ([Figures 1](#fig1){ref-type="fig"}Q, [S2](#mmc1){ref-type="supplementary-material"}E, [S4](#mmc1){ref-type="supplementary-material"}G, and S4H, [Table 1](#tbl1){ref-type="table"}). HSCs, CMPs, and MEPs displayed a more expected reconstitution pattern. Notably, CMP^F^ gave rise to far greater numbers of RBCs than GMs, with Plt production roughly equaling that of GM generation ([Figures 1](#fig1){ref-type="fig"}P and [S2](#mmc1){ref-type="supplementary-material"}D, [Table 1](#tbl1){ref-type="table"}). Similarly, although MPP^F^ displayed complete multipotency, they produced RBCs and platelets in much greater abundance than they produced nucleated mature cells ([Figures 1](#fig1){ref-type="fig"}N and [S2](#mmc1){ref-type="supplementary-material"}B, [Table 1](#tbl1){ref-type="table"}), defying reports that FLK2 expression signifies loss of MegE potential. Overall, the proportions of different mature cell types produced by all erythromyeloid-competent cells were strikingly similar ([Figures 1](#fig1){ref-type="fig"}M--1R and [S2](#mmc1){ref-type="supplementary-material"}A--S2F, [Table 1](#tbl1){ref-type="table"}).

Direct Comparison of the Mature Cell Production Capacity of Progenitor Populations {#sec2.3}
----------------------------------------------------------------------------------

To assess the relative reconstitution capacity of each progenitor cell type, we then compared the total output of each mature cell type per transplanted HSPC. Each HSC generated more of each mature cell type than any progenitor tested ([Figures 2](#fig2){ref-type="fig"}A--2E). In addition, the time between transplantation and the peak of mature cell production (time to peak) was the longest for HSCs, and mature cells persisted without evidence of decline ([Figures 2](#fig2){ref-type="fig"}A--2E and 2A′--2E′). These properties are consistent with self-renewal and with HSCs existing at the top of the hematopoietic hierarchy ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Per transplanted cell, MPP^F^ gave rise to more RBCs, platelets, GMs, B cells, and T cells than any lineage-restricted progenitor ([Figures 2](#fig2){ref-type="fig"}A--2E). In addition, the time to peak for mature cell production from transplanted MPP^F^ was shorter than for HSCs, but longer compared with lineage-restricted progenitors ([Figures 2](#fig2){ref-type="fig"}A--2E and 2A′--2E′). Likewise, the timing and total cell production from both CMP populations were in between those of the MPP^F^ and MEPs. Relative to CMP^F^, CMPs displayed more robust RBC and Plt generation ([Figures 2](#fig2){ref-type="fig"}A and 2B; 2A′--2B′), while CMP^F^ excelled in GM production ([Figures 2](#fig2){ref-type="fig"}C and 2C′). While the capacity of CMP^F^ to produce RBCs and platelets *in vivo* contrasts with *in vitro* data where MegE output from CMP^F^ was not observed ([@bib28]), our results are consistent with the relative lineage preferences from previously described *in vitro* data, with CMP^F^ exhibiting a relative preference for GM production compared with CMP ([Figures 2](#fig2){ref-type="fig"}A′--2C′ and [Table 1](#tbl1){ref-type="table"}). GMPs produced the same cell types as CMPs and CMP^F^, but in fewer numbers and with the shortest time to peak for any HSPC ([Figures 2](#fig2){ref-type="fig"}A--2E and 2A′--2E′). Overall, these data are consistent with the developmental relationship between HSPCs displayed in [Figure S1](#mmc1){ref-type="supplementary-material"}A.

MPP^F^ Give Rise to Myeloid Progenitors *In Vivo* {#sec2.4}
-------------------------------------------------

The lineage potential and absolute number of cells produced can provide insights into the relative hierarchy of cell populations, but not direct mother-daughter relationships. To directly determine if MPP^F^ can give rise to erythro- and erythromyeloid-restricted progenitors, and to assess the extent of expansion of various progenitor populations, we performed phenotypic, quantitative, and functional analysis of donor-derived cells shortly after transplantation ([Figure 3](#fig3){ref-type="fig"}A). Two days after transplantation of HSCs or MPP^F^, the phenotype of the donor cells in the recipient BM remained similar to their respective phenotype prior to transplantation ([Figures 3](#fig3){ref-type="fig"}B and 3C). By days 7 and 14, transplanted HSCs maintained the self-renewing HSC pool while also repopulating phenotypic MPPs, "classical" ([Figures 3](#fig3){ref-type="fig"}D^1^ and 3D^2^) and "alternative" myeloid progenitors ([Figures 3](#fig3){ref-type="fig"}E^1^ and 3E^2^), as well as erythroid progenitors (EPs) and mature GM cells ([Figures 3](#fig3){ref-type="fig"}H^1^ and H^2^). Few HSC-derived B and T cells were detected within the 14 day analysis period. BM analyses at days 4, 7, 11, and 14 revealed that MPP^F^ repopulated all types of erythromyeloid progenitors and mature cells ([Figures 3](#fig3){ref-type="fig"}F^1^--3I^4^). Quantification of the absolute donor-derived cell numbers showed substantial expansion of donor-derived cells during the analysis period ([Figures 3](#fig3){ref-type="fig"}D^1−2^′--3I^1−4^′ and [S4](#mmc1){ref-type="supplementary-material"}A--S4D). By day 14, the transplanted HSCs had given rise to ∼2 million and MPP^F^ to nearly 4 million myeloid progenitor cells ([Figures 3](#fig3){ref-type="fig"}D^1−2^′--3G^1−4^′). While MPP^F^ clearly produced more B cells compared with HSCs within this time frame ([Figures 3](#fig3){ref-type="fig"}H^1^′--3I^4^′), the proportions of progenitor cells generated by HSCs and MPP^F^ were similar ([Figures 3](#fig3){ref-type="fig"}D^1^′--3I^4^′). For example, comparing CMP/GMP/MEP proportions from HSCs at day 14 with CMP/GMP/MEP from MPP^F^ at day 11 revealed that distributions were not statistically significantly different ([Figures 3](#fig3){ref-type="fig"}D^1−2^′ versus 3F^1−4^′). Indeed, GMPs were the second most abundantly produced progenitor population from both HSCs (∼1.3 million GMPs by day 14) and MPP^F^ (∼2.2 million GMPs; approximately 2-fold more than from HSCs), after EPs (∼13 million from HSCs and, as with GMP generation, ∼2-fold more \[∼26 million\] EPs from MPP^F^). Interestingly, these experiments did not reveal a clear hierarchy between CMPs and their presumed GMP and MEP descendants, as GMPs outnumbered CMPs at all time points from both HSCs and MPP^F^. Secondary transplantation of HSC- and MPP^F^-derived CMPs, GMPs, MEPs, and EPs confirmed that these populations have the same lineage potential as the corresponding cell population in primary transplantation ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4L). MPP^F^ were also capable of producing phenotypic CLPs, although in significantly lower numbers compared with erythromyeloid-restricted progenitors (∼35- and ∼220-fold differences at days 7 and 14, respectively; [Figures S4](#mmc1){ref-type="supplementary-material"}M and S4N). Quantitatively, these experiments demonstrate that there is substantial expansion in progenitor cell numbers in the BM soon after transplantation, that HSCs and MPP^F^ produce various erythromyeloid progenitors in roughly the same proportions, and that MPP^F^ produce more erythromyeloid- than lymphoid-restricted progenitor cells. Qualitatively, these data provide direct evidence that transplanted MPP^F^ produce all types of erythromyeloid- and lymphoid-competent progenitor cells, consistent with full multipotency.Figure 3Both HSCs and MPP^F^ Generate all Types of Erythromyeloid Progenitors after Transplantation(A) Schematic of HSC and MPP^F^ transplantation from UBC-GFP mice, short-term analysis of donor-derived progenitor cells, and subsequent functional analysis of the same donor-derived progenitor cells by secondary transplantation.(B--I) Analysis of donor-derived cells in the BM of recipients shortly after transplantation of HSCs and MPP^F^. Cells were pre-gated on GFP+ to display only donor-derived cells. (B and C) At day 2 post-transplantation, the phenotype of GFP+ cells in the BM of sublethally irradiated (500 rad) recipient mice was predominantly the same as the phenotype of the input cell type. (D, E, and H) Transplanted HSCs gave rise to phenotypic classical CMPs, GMPs, and MEPs (D^1^ and D^2^); progenitors defined by alternative markers as MkP, "GMP," pre-GM, pre-EP, pre-CFU-E, and pre-MegE (E^1^ and E^2^); and EP and GM cells (H^1^ and H^2^) by days 7 and 14 post-transplantation into lethally irradiated (1,000 rad) recipients. Few HSC-derived B and T cells were observed at these time points (H^1^ and H^2^). (F, G, and I) Transplanted MPP^F^ gave rise to phenotypic classical CMPs, GMPs, and MEPs (F^1^--F^4^); MkP, "GMP," pre-GM, pre-EP, pre-CFU-E, and pre-MegE (G^1^--G^4^); and EP, GM, and B and T cells (I^1^--I^4^) by days 4, 7, 11, and 14 post-transplantation. (D^1^′--I^4^′) Quantification of results displayed in (D--I), respectively, demonstrated substantial expansion in donor-derived cell numbers during the course (4--14 days) of the experiments. Most comparisons of the absolute cell numbers between time points and between HSCs and MPP^F^ were significantly different; however, the proportions of progenitor cells generated were similar. For example, both HSCs and MPP^F^ generated more GMPs than MEPs and CMPs, and the proportions of CMP/GMP/MEP generated by HSCs at day 11 and MPP^F^ at day 14 were not significantly different from each other (Student\'s two-tailed t test for HSCs; one-way ANOVA with multiple post hoc comparisons for MPP^F^; D^1^′--I^4^′). n = 3 or more recipients in two or more independent experiments for each donor cell type and analysis time point.Data are displayed as means ± SEM. Abbreviations for pre-gating of (H^1^--I^4^): Ery, TER-119; Ly, CD3 and B220; My, Gr1 and Mac1. FACS, fluorescence-activated cell sorting; WT, wild-type. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Transplantation of Single MPP^F^ Provides Multilineage Reconstitution {#sec2.5}
---------------------------------------------------------------------

It is clear from the data presented in [Figures 1](#fig1){ref-type="fig"}M, 1N, [3](#fig3){ref-type="fig"}F--3I, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B that transplantation of multiple MPP^F^ results in a cell production profile similar to that of HSCs. However, population data cannot determine if the MPP^F^ compartment is functionally homogeneous, with each cell being multipotent ([Figure 4](#fig4){ref-type="fig"}A, multipotency model; [@bib8]), if MPP^F^ are a heterogeneous population of committed progenitors that share a common phenotype ([Figure 4](#fig4){ref-type="fig"}A, commitment model), or a combination of the two. To differentiate between these possibilities, we implemented two *in vivo* clonal approaches: single-cell transplantation and analysis of single-cell-derived colony-forming units of the spleen (CFU-S).Figure 4Single HSCs and MPP^F^ Reconstituted Both Myeloid and Lymphoid Lineages *In Vivo*(A) Alternative models of MPP^F^ multipotency. The multilineage reconstitution by MPP^F^ transplanted in bulk ([Figures 1](#fig1){ref-type="fig"}B and 1N) may be derived from clonally multipotent MPP^F^ (left) or from the combined contribution of lineage-committed cells with a shared MPP^F^ surface phenotype (right).(B) Summary of the results from single transplanted HSCs and from single and multiple MPP^F^. p = 0.05 for 1 HSC versus 25 MPP^F^; p \> 0.1 for 1 HSC versus 5 MPP^F^; p \< 0.05 for 1 HSC versus 1 MPP^F^ by chi-square test of independence in reconstitution patterns.(C--F) Lineages detected in individual lethally irradiated (1,000 rad) recipients receiving either single HSCs (C) or 1 (D), 5 (E), or 25 (F) MPP^F^. Mature cell detection by flow cytometry is indicated for each recipient and cell type by a filled square (RBCs, red; platelets, pink; GMs, orange; B cells, blue; T cells, teal).(G--N) (G--J) Percentage donor chimerism and (K--N) distribution of mature cells from single HSCs (G and K) and 25 (J and N), 5 (I and M), or single (H and L) MPP^F^. Representative recipients that displayed multilineage reconstitution are shown.(O) B cell numbers display a rapid and more drastic decline (2,000-fold) after lethal irradiation than other mature cell types (4- to 150-fold for RBCs and T cells, respectively). Data displayed are fold change in mature cell numbers in the PB of lethally irradiated (1,000 rad) mice over time. n = 4.(P--T) The magnitude and timing of host cell depletion and recovery affect the ability to detect reconstitution from transplanted progenitor cells. Numbers from (O) were superimposed with the kinetics of mature cell generation by HSCs and MPP^F^ for each lineage, and displayed relative to the peak reconstitution (set at 1.00) for each population. RBCs (P), platelets (Q), GMs (R), B cells (S), and T cells (T). All data are from at least three independent experiments.See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

Single-cell transplantation of one HSC or one MPP^F^ led to detectable levels of donor-derived cells in 19% and 17% of mice, respectively ([Figures 4](#fig4){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}). Eight of the 20 reconstituted recipients of a single HSC had donor-derived cells of all five lineages investigated ([Figures 4](#fig4){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}). This may be an underestimation of their true capacity, as some quiescent HSCs do not produce progeny until many weeks after transplantation or until secondary transfer ([@bib44]). Fifty-five percent of mice reconstituted with a single HSC produced cells of at least one myeloid lineage (RBCs, platelets, and/or GMs) and one lymphoid lineage (B cells and/or T cells) and were therefore categorized as multipotent ([Figures 4](#fig4){ref-type="fig"}B and 4C). The remaining positive recipients of single HSCs produced only myeloid cells, whereas none produced only lymphoid cells ([Figures 4](#fig4){ref-type="fig"}B and 4C). None of the single MPP^F^ gave rise to all five cell types analyzed. Importantly, however, some single MPP^F^ gave rise to four different types of mature cells, and a considerable fraction of single MPP^F^ (43%; 9/21) generated both myeloid and lymphoid cells ([Figures 4](#fig4){ref-type="fig"}B and 4D). Increasing the number of transplanted MPP^F^ to 5 or 25 cells led to a higher frequency of recipients with detectable donor cells ([Figure 4](#fig4){ref-type="fig"}B), an increased number of cell types detected ([Figures 4](#fig4){ref-type="fig"}D--4F), and an increase in donor chimerism levels ([Figures 4](#fig4){ref-type="fig"}H--4J; average overall reconstitution from 1, 5, and 25 MPP^F^ was 0.9%, 1.5%, and 2.2%, respectively). Twenty-five MPP^F^ were sufficient for combined myeloid and lymphoid detection in 100% of recipients, whereas mice transplanted with 5 or 1 MPP^F^ or a single HSC were multilineage reconstituted at lower frequencies (37.5%, 43%, and 55%, respectively; [Figures 4](#fig4){ref-type="fig"}B--4F). Although a single MPP^F^ did not contribute as robustly to recipient chimerism as a single HSC ([Figures 4](#fig4){ref-type="fig"}G and 4H; average overall reconstitution levels were 0.9% and 8%, respectively), more RBCs than any other mature cell type were generated from both HSCs and MPP^F^ ([Figures 4](#fig4){ref-type="fig"}K--4N).

Despite high frequency of combined myeloid and lymphoid reconstitution by MPP^F^, we noted that MPP^F^ led to only GM, only B cell, or combined GM/B cell reconstitution of some recipients, whereas HSCs did not. In addition, some myelo/lympho reconstitution occurred in unexpected combinations, such as only RBCs and B cells (mouse 6 for single MPP^F^, mouse 9 for 25 MPP^F^, and mice 8 and 9 for 5 MPP^F^). GM and B cells occurred together in several mice, without detection of T cells. Indeed, T cell readout was the most difficult lineage to detect from both HSC and MPP^F^ transplants ([Figures 4](#fig4){ref-type="fig"}C--4F). As different mature cell types in the host are depleted to different extents upon sublethal ([Figure 1](#fig1){ref-type="fig"}H) and lethal ([Figure 4](#fig4){ref-type="fig"}O) irradiation, and donor-derived progeny are produced with different kinetics from different HSCs and MPP^F^ ([Figures 2](#fig2){ref-type="fig"}A′--2E′), we hypothesized that the kinetics of host and donor cells differentially affects donor-derived cell detection. Superimposing the decline and recovery of host cells with the production of mature cells by HSCs or MPP^F^ revealed that RBC production from both HSCs and MPP^F^ largely coincided with the reduction in host RBCs ([Figure 4](#fig4){ref-type="fig"}P), facilitating detection of donor-derived RBCs in recipient mice. In contrast, neither HSCs nor MPP^F^ produce large numbers of T cells until after host T cell numbers have significantly recovered ([Figure 4](#fig4){ref-type="fig"}T), contributing to poor detection of T cells in mice transplanted with a single cell ([Figures 4](#fig4){ref-type="fig"}C and 4D). Similarly, the timing of GM and B cell production from MPP^F^ occurs near the low point of host GMs and B cells, whereas the main contribution of HSCs to GMs and B cells occurs after host cell recovery ([Figures 4](#fig4){ref-type="fig"}R and 4S). The fact that B cells are the host cell type most affected by irradiation ([Figures 1](#fig1){ref-type="fig"}H and [4](#fig4){ref-type="fig"}O) and that MPP^F^ produce B cells prior to host recovery, whereas HSCs do not ([Figure 4](#fig4){ref-type="fig"}S), contributes to the relatively high frequency of B cell detection in mice transplanted by a single MPP^F^, as well as the more apparent contribution of CLP^F^ to B cells than to T cells ([Figures 1](#fig1){ref-type="fig"}G, 1S, and [S6](#mmc1){ref-type="supplementary-material"}).

Multilineage Reconstitution from Single HSCs and MPP^F^ in Spleen Colony Assays {#sec2.6}
-------------------------------------------------------------------------------

To test the multipotency of clonal HSCs and MPP^F^ by an independent method, we analyzed donor-derived CFU-S. Like single-cell transplants, this assay measures clonal lineage potential, as each colony consists of progeny from a single cell ([@bib5], [@bib43]). In support of the clonal origin of CFU-S, we observed only single-color colonies when a mixture of Tomato+ cells and GFP+ cells was transplanted into the same recipient ([Figure 5](#fig5){ref-type="fig"}A). To test for multilineage potential of single cells, we examined individually dissected CFU-S for EPs, megakaryocytes (Megs), GMs, and B cells ([Figure 5](#fig5){ref-type="fig"}B). It is highly improbable that CFU-S colonies were contaminated with circulating, donor-derived mature cells, as donor contribution within individual CFU-S was substantially higher than the donor cell chimerism in the PB (compare [Figures 5](#fig5){ref-type="fig"}B and 5C). T cell output was not assessed, as T cells require extended development in the thymus and are not produced in the spleen or in the time frame of this assay.Figure 5Multilineage Reconstitution by Single HSCs and MPP^F^ in *In Vivo* Spleen Colony Assays(A) In support of the clonal origin of spleen colonies, CFU-S were composed of only a single color, either red or green, after transplantation of a mixture of Tomato+ and GFP+ cells. Representative fluorescence microscopy images are shown.(B--F) Spleen colonies derived from single HSCs or MPP^F^ contain erythroid, megakaryocytic, GM, and B cell lineages. Donor cells from UBC-GFP mice were transplanted into lethally irradiated (1,000 rad) mice. CFU-S were dissected and analyzed by flow cytometry at the time point post-transplantation of largest colony size; HSCs on day 13.5 (n = 13), MPP^F^ on day 11.5 (n = 18), CMPs on day 9.5 (n = 16), CMP^F^ on day 9.5 (n = 8), and MEPs on day 8.5 (n = 9). (B) Gating strategy and analysis of a representative MPP^F^-derived CFU-S. The percentages of donor-derived (GFP+) cells for each cell type within representative colonies are shown in the histograms on the right, with gating strategies shown on the left. (C) Substantially lower donor contribution was observed in the PB than within CFU-S (B), indicating that the detection of multiple lineages within a colony is not due to contamination of circulating cells. Of note, there were no detectable EPs or Megs in the PB. Representative flow cytometry plots are from a recipient of MPP^F^. (D) Proportion of individual CFU-S containing detectable EPs, Megs, GMs, and/or B cells. (E) Summary of the CFU-S data shown in (D). The colony type distribution was not significantly different for HSCs versus MPP^F^ (p \> 0.1; chi-square test of independence). (F) The frequency of EPs, Megs, GMs, and B cells in dissected CFU-S colonies from (D). Percentages are shown as donor-derived (GFP+) cells only. Data represent four independent experiments with a total of 12--17 mice per group.

Of 13 HSC-derived CFU-S, six (46%) contained all four lineages that can be detected in this assay (EPs, Megs, GMs, and B cells; [Figure 5](#fig5){ref-type="fig"}D, red bar; [Figure 5](#fig5){ref-type="fig"}E). The remaining colonies lacked B cells and were thus a mixture of myeloid lineages. Similarly, six of the 18 (33%) single-MPP^F^-derived colonies contained all four lineages ([Figures 5](#fig5){ref-type="fig"}D and 5E). Other MPP^F^-derived CFU-S contained various combinations of myeloid only or myeloid plus B cells. The proportions of myelo/lympho, myeloid only, or lymphoid only colonies produced by HSCs versus MPP^F^ were not significantly different ([Figure 5](#fig5){ref-type="fig"}E). All colonies visible to the eye contained erythroid cells. In fact, the vast majority of total cells produced were erythroid cells ([Figure 5](#fig5){ref-type="fig"}F), and CFU-S derived from CMP, CMP^F^, and MEP contained only EPs ([Figure 5](#fig5){ref-type="fig"}D). The absence of additional lineages from myeloid progenitors is likely due to their reduced total cell production compared with HSCs and MPP^F^ ([Figures 2](#fig2){ref-type="fig"}A--2C), limiting our ability to detect mature cells that are not produced in as high abundance as erythrocytes. The CFU-S data, like the single-cell transplantations, demonstrate that a substantial fraction of both HSCs and MPP^F^ is multipotent at the single-cell level.

Discussion {#sec3}
==========

A Quantitative Perspective of Progenitor Repopulation Capacity {#sec3.1}
--------------------------------------------------------------

By simply quantifying the absolute number of mature cells generated per transplanted stem and progenitor cell, we provide a new perspective of the regenerative capacity of HSCs and several progenitor populations. Our strategy revealed that all progenitor cells with myeloid potential produce far more RBCs than any other cell type ([Table 1](#tbl1){ref-type="table"} and [Figures 1](#fig1){ref-type="fig"}M--1S, [2](#fig2){ref-type="fig"}A--2E, 2A′--2E′, [3](#fig3){ref-type="fig"}A--3F, [4](#fig4){ref-type="fig"}K--4N, and [5](#fig5){ref-type="fig"}D--5F). As illustrated by the concordance with previous findings when the same results were displayed as traditional donor chimerism ([Figures 1](#fig1){ref-type="fig"}A--1G), our results are not due to differences in gating strategies, cell population purity, or transplantation methods. Rather, the new insights were reached by eliminating the drastically variable fluctuations in host cell disappearance and recovery ([Figures 1](#fig1){ref-type="fig"}H and [4](#fig4){ref-type="fig"}O) and by taking into account the absolute numbers of each mature cell type, including RBCs and platelets, produced by each stem and progenitor cell ([Figures 2](#fig2){ref-type="fig"}A--2E, 2A′--2E′, and [S2](#mmc1){ref-type="supplementary-material"}). As transplanted donor cells differ not only in the types of cells generated, but also in the number, timing, and duration of mature cell production, each progenitor cell has a distinct reconstitution pattern. In addition, the half-lives of mature cell types vary considerably. Collectively, these dynamics differentially affect the ability to detect and quantify the contributions of different donor populations to each mature lineage, as exemplified in [Figures 4](#fig4){ref-type="fig"}P--4T and [S6](#mmc1){ref-type="supplementary-material"}. Absolute quantification of donor-derived cells removes host variables and therefore facilitates comparative assessment of reconstitution both across lineages and between transplanted populations.

Unexpected Lineage Potential of Hematopoietic Progenitor Populations {#sec3.2}
--------------------------------------------------------------------

The lineage potential that we uncovered was in some cases unexpected. For example, GMPs have been reported to express few erythroid-associated genes and to lack MegE potential ([@bib2], [@bib15], [@bib31], [@bib33]), and CMP^F^ produce few Meg/erythroid colonies *in vitro* ([@bib28]), whereas our experiments here revealed that CMP^F^ and GMPs produce RBCs and platelets ([Figures 1](#fig1){ref-type="fig"}D, 1E, 1P, 1Q, [2](#fig2){ref-type="fig"}A--2C, 2A′--2C′, [3](#fig3){ref-type="fig"}A--3J, [S2](#mmc1){ref-type="supplementary-material"}, and [S4](#mmc1){ref-type="supplementary-material"}E--S4H, [Table 1](#tbl1){ref-type="table"}). Significant heterogeneity of myeloid progenitor populations, especially classical CMPs, has been reported ([@bib23], [@bib31], [@bib32]), confounding interpretation of lineage potential. While the purity of bulk populations is not absolute, contamination cannot explain the differences between the lineage potential apparent in [Figures 1](#fig1){ref-type="fig"}A--1G and 1M--1S, as these data are derived from the exact same experiments. Other possible contributors to the contradictory findings include differences between the *in vitro* and the *in vivo* assay conditions, limits of detection, and the relatively recent development of mice that make it possible to directly track RBCs and platelets *in vivo*. The cell production capacity varies drastically between different progenitors: our estimates revealed that each MPP^F^ produces, on average, ∼800,000 cells, whereas one GMP gives rise to ∼47 progeny (43 RBCs, 1 Plt, and 4 GMs; [Figures 2](#fig2){ref-type="fig"}A′--2E′). The low burst size of GMPs precludes detection of progeny in single-cell transplants and in CFU-S; thus, the data presented here do not conclusively rule out that RBC and/or Plt generation from presumed GMPs is from "contaminating" cells. Notably, whereas we readily detected GFP+ RBCs and platelets in every recipient of GMPs in both primary and secondary transplantation experiments ([Figures 1](#fig1){ref-type="fig"}E, 1Q, [S4](#mmc1){ref-type="supplementary-material"}G, and S4H), we did not observe RBC or Plt production from CLPs ([Figures 1](#fig1){ref-type="fig"}G and 1S) or platelets from EPs ([Figures S4](#mmc1){ref-type="supplementary-material"}K--S4L), indicating that the technical purity of our transplanted cell populations is good. In future studies we will test whether GMPs, like MPP^F^, fit the "default" model proposed later by displaying significant *in vivo* MegE potential that is not readily detected *in vitro*. In contrast, the numbers of RBCs produced by CMPs and CMP^F^ (averaging ∼140,000 and 35,000, respectively) were sufficient for detection of EPs in CFU-S ([Figure 5](#fig5){ref-type="fig"}D), whereas detection of platelets from CMPs, CMP^F^, GMPs, and MEPs required transplantation of higher numbers of progenitors. We previously demonstrated that Flk2+ MPPs give rise to all lineages, including erythroid cells, *in situ* both at steady state and under stress, as well as upon transplantation ([@bib8], [@bib7], [@bib15]). Collectively, our results indicate that it is difficult to separate functional RBC and Plt potential from GM potential *in vivo*, reinforcing the existence of functional CMPs and the retention of RBC capability across several phenotypically distinct populations.

CLP^F^ Appear Restricted to B and T Cell Generation {#sec3.3}
---------------------------------------------------

The only population in our study that did not produce RBCs and platelets was CLP^F^. CLP^F^ also lacked detectable GM potential and therefore appear committed to the lymphoid fate, in agreement with their initial designation as CLPs ([@bib20]) and with *in vivo* lineage tracing experiments ([@bib37]). Interestingly, while B cell production was readily detectable, T cell capacity was more apparent by absolute quantification than by donor chimerism data (compare [Figures 1](#fig1){ref-type="fig"}G--1S). The relative difficulty in detecting CLP^F^-derived T cells can be attributed, in part, to host T cells being less affected by irradiation compared with host B cells (∼20-fold versus ∼1,000-fold, respectively; [Figure 1](#fig1){ref-type="fig"}H) and because host T cell numbers recover before CLP^F^-derived T cells start accumulating (approximately day 19; [Figures 1](#fig1){ref-type="fig"}S and [S6](#mmc1){ref-type="supplementary-material"}). In contrast, CLP^F^-derived B cells are detected as early as day 9 after transplantation, closely coinciding with the sharp reduction in host B cells ([Figure S6](#mmc1){ref-type="supplementary-material"}). Their more limited lineage potential and lower expansion capacity are consistent with CLP^F^ residing hierarchically downstream of MPP^F^. However, our calculations estimated that one MPP^F^ gives rise to equal numbers of B cells (∼2,500) and T cells (∼2,700), whereas one CLP^F^ gives rise to 10-fold more B cells than T cells (420 versus 42) ([Figures 2](#fig2){ref-type="fig"}D′ and 2E′). This appears inconsistent with a direct and exclusive MPP^F^-to-CLP^F^ transition, but rather evokes additional intermediate populations and/or flexibility in differentiation pathways from upstream progenitors.

Multilineage Differentiation Potential of Single HSCs and MPP^F^ {#sec3.4}
----------------------------------------------------------------

It is clear from both the chimerism ([Figure 1](#fig1){ref-type="fig"}B) and the absolute cell number data ([Figures 1](#fig1){ref-type="fig"}N and [2](#fig2){ref-type="fig"}A--2E), as well as previous publications ([@bib15], [@bib23], [@bib44]), that despite downregulation of erythroid-associated genes ([@bib15], [@bib24]), MPP^F^ are multipotent at the population level. Here, we also showed that a substantial fraction of MPP^F^ is multipotent at the single-cell level. In CFU-S assays, MPP^F^ produced both myeloid and lymphoid cells in 67% of the colonies, with the remaining colonies consisting of myeloid cells only ([Figures 5](#fig5){ref-type="fig"}D and 5E). While the CFU-S frequency from MPP^F^ is lower than that from HSCs (∼1/78 versus 1/33; [@bib3], [@bib15]), CFU-S capability is clearly an underestimation of the MegE potential of a cell, as far more than 1/33 HSCs are multipotent in other assays. Indeed, the CFU-S frequency increases ∼10-fold when HSCs or MPP^F^ are injected directly into the spleen as opposed to intravenously ([@bib3]). Collectively, these data demonstrate that the ability of MPP^F^ to generate MegE cells is substantially greater than estimated by CFU-S alone.

Similar proportions of HSCs and MPP^F^ displayed combined myelo/lymphoid potential at the clonal level upon single-cell transplantation (55% of HSCs and 43% of MPP^F^; [Figures 4](#fig4){ref-type="fig"}B and 4C). Our numbers are similar to those of Yamamoto et al., who found that 56% (9/16 mice) of "LMPPs" (in their report defined as KLS CD34+ FLK2+, a population significantly overlapping with our MPP^F^) displayed combined myelo/lymphoid readout ([@bib44]). *In vivo* evidence for the existence of clonal MPP was also provided by *in situ* barcoding studies ([@bib35], [@bib41]). The exact proportion of uncommitted cells within the HSC and MPP^F^ compartment is difficult to estimate, as variable lineage outputs could be a result of detection limits (progeny were produced but not in sufficient numbers to detect), stochasticity (the transplanted cell happened to encounter a particular combination of cytokines), population heterogeneity (a proportion of the cells are multipotent, whereas some are not), or a combination of the three. Few studies have tested the full lineage potential of MPP^F^, but the heterogeneity of HSCs has been tested and debated extensively ([@bib14], [@bib17], [@bib19], [@bib38]). The HSC results are highly relevant for the heterogeneity of MPP^F^: a lineage-restricted cell (a committed "HSC") cannot give rise to a cell with greater lineage potential (a multipotent MPP). Thus, the proportion of multipotent cells within the MPP^F^ fraction must be equal to or smaller than the fraction of HSCs that are multipotent ([Figure 4](#fig4){ref-type="fig"}A; [@bib8]). Conversely, if some MPP^F^ are uncommitted, an equal or greater proportion of HSCs and other upstream populations should also be uncommitted. In our experiments, the frequency of single cells with combined myelo/lympho potential is similar for HSCs and MPP^F^ (55% and 43% for singly transplanted HSCs and MPP^F^, respectively, and 46% and 67% for HSCs and MPP^F^ in CFU-S). Given that it is harder to detect progeny from MPP^F^ than from HSCs, the extent of lineage restriction upon the transition from HSCs to MPP^F^ appears quite low. The existence of fully multipotent progenitor cells is consistent with the notion that steady-state hematopoiesis is largely sustained by MPPs rather than HSCs ([@bib9], [@bib41]).

RBC Production as the Default Hematopoietic Fate {#sec3.5}
------------------------------------------------

Previous studies have shown that substantial amplification of RBC production occurs at the level of erythroid-committed progenitors and precursors. While the overall dominance of RBC production should not be unexpected, models of hematopoietic differentiation rarely take the vastly different numbers of mature cells into account. The fact that cell populations like MPP^F^ and GMPs, despite their poor ability to generate MegE cells *in vitro* and clear downregulation of erythroid-driving genes, generate RBCs not only in the largest absolute numbers, but also in roughly similar relative proportions compared with other HSPCs, was particularly surprising. This discordance of gene expression and functional differentiation potential may hamper efforts to construct lineage maps based on transcriptome data. To reconcile these apparent discrepancies, we propose a model based on functional lineage potential where RBC production is the default pathway ([Figure 6](#fig6){ref-type="fig"}). In this model, MegE potential is gained upon specification of HSCs from a hematovascular precursor. HSCs, at all stages of development, thus have inherent capability to generate RBCs and platelets, but not necessarily GMs, T cells, and B cells. This notion makes sense through ontogeny and as a mechanism to ensure survival, and fits with newly proposed views of human hematopoiesis ([@bib27]). Our model proposes that differentiation into alternative fates is accomplished downstream of HSCs by the combination of two mechanisms: increased expression of proteins promoting GM, B cell, and/or T cell differentiation and a concurrent decrease in expression of genes driving RBC and Plt generation. *In vivo*, continuous expression of MegE-promoting genes does not appear necessary for retention of RBC and Plt capability, conceivably because MegE differentiation has already been initiated. Unless exposed to sufficient concentrations of factors to alter this path, most hematopoietic progenitors will therefore produce primarily RBCs and platelets. Conversely, downregulation of MegE-promoting genes may be necessary for deviation from this default pathway to allow for the relatively rare production of GMs, B cells, and T cells. When the default pathway is interrupted (removal of cells from their natural environment), progenitors that have downregulated MegE-specifying receptors (MPP^F^, CMP^F^, and GMPs) are unable to *reinitiate* MegE production. Thus, they perform relatively poorly in MegE assays *in vitro* ([@bib1], [@bib28], [@bib33]). As MPP^F^, CMP^F^, and GMPs have acquired expression of receptors that promote GM or lymphoid fates, they are reactive to the corresponding cytokines and consequently readily differentiate *in vitro* into cell types that normally (*in vivo*) represent alternative fates. The proposed model influences our understanding of erythroid-specific versus pan-hematopoietic disorders, and also provides explanations for the discordant lineage potential by *in vivo* and *in vitro* strategies and for the disconnection between gene expression patterns and functional cell production *in vivo*. Collectively, MPP^F^ may be viewed more accurately as cells that have *gained* GM, B, and T potential than as cells that have *lost* MegE potential. This view is supported by our previous demonstration that all hematopoietic lineages are derived via an FLK2+ stage *in situ* and upon transplantation ([@bib7], [@bib8]), by FLK2 promoting expansion of all mature blood cell types ([@bib3]), and by recent reports pointing to MPPs, rather than HSCs, as the major source of mature hematopoietic cells during steady-state hematopoiesis *in situ* ([@bib9], [@bib41]).Figure 6Hematopoietic Differentiation Model in which Erythroid Production Represents the Default Fate of HSCsBoth functional experiments and gene expression data indicate that the capacity to generate RBCs and platelets is acquired upon specification of HSCs from a hematovascular precursor. Despite downregulation of genes that drive MegE development, RBC and Plt production remains the predominant fate of MPP^F^ and other non-lymphoid committed progenitors. Relatively rare production of GMs and B and T cells occurs through combined downregulation of MegE drivers and a gain of gene products promoting the alternative fates. Initiation of non-MegE fates in MPP^F^ may thus be viewed as gain of GM and lymphoid potential, rather than loss of capacity to generate RBCs and/or platelets.

Experimental Procedures {#sec4}
=======================

Transplantation Assays {#sec4.1}
----------------------

Hematopoietic cells were isolated from BM isolated from murine femurs and tibias from wild-type (C57BL/6) or UBC-GFP mice ([@bib36]) in accordance with UCSC IACUC guidelines, as described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} and previously ([@bib4], [@bib3], [@bib40], [@bib39], [@bib42]).

Mature Cell Quantification {#sec4.2}
--------------------------

A known volume of PB was mixed with an antibody solution containing a known quantity of Calibrite APC beads prior to flow cytometry analysis. For tissues, a known quantity of beads was added to each tissue preparation prior to antibody staining and analysis. The number of beads counted by flow cytometry was used to calculate the number of mature cells per microliter of blood or within each tissue. The distribution of mature hematopoietic cells in a mouse was measured in the blood obtained by perfusion, in BM by analysis of two femurs and tibias, in spleen, in thymus, and in lymph nodes (inguinal, axillary, and superficial cervical).

Single-Cell Transplants {#sec4.3}
-----------------------

Individual HSCs and MPP^F^ were double-sorted into separate wells on Terasaki plates using a FACSAria III from lineage-depleted BM cells from UBC-GFP mice, similar to our previous reports ([@bib10], [@bib11]) and as detailed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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